Which Bisphosphonate? It’s the Compliance!: Decision Analysis
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: The best options of several bisphosphonates for prevention of osteoporotic fractures in postmenopausal women remain controversial. We determined which bisphosphonate provides better efficacy in prevention of osteoporotic fractures using a decision analysis tool, in terms of quality of life. Methods: A decision analysis model was constructed containing final outcome score and the probability of vertebral and hip fracture within 1 year. Final outcome was defined as health-related quality of life, and was used as an utility in the decision tree. Probabilities were obtained by literature review, and health-related quality of life was evaluated by consensus committee. A roll back tool was used to determine the best bisphosphonate, and sensitivity analysis was performed to compensate for decision model uncertainty. Results: The decision model favored bisphosphonate with higher compliance in terms of quality of life. In one-way sensitivity analysis, ibandronate was more beneficial than the others, when probability of compliance on ibandronate was above 0.589. Conclusions: In terms of quality of life, the decision analysis model showed that compliance was most important for patients in real world, regardless of type of bisphosphonate.
Abstract
Background: The best options of several bisphosphonates for prevention of osteoporotic fractures in postmenopausal women remain controversial. We determined which bisphosphonate provides better efficacy in prevention of osteoporotic fractures using a decision analysis tool, in terms of quality of life. Methods: A decision analysis model was constructed containing final outcome score and the probability of vertebral and hip fracture within 1 year. Final outcome was defined as health-related quality of life, and was used as an utility in the decision tree. Probabilities were obtained by literature review, and health-related quality of life was evaluated by consensus committee. A roll back tool was used to determine the best bisphosphonate, and sensitivity analysis was performed to compensate for decision model uncertainty. Results: The decision model favored bisphosphonate with higher compliance in terms of quality of life. In one-way sensitivity analysis, ibandronate was more beneficial than the others, when probability of compliance on ibandronate was above 0.589. Conclusions: In terms of quality of life, the decision analysis model showed that compliance was most important for patients in real world, regardless of type of bisphosphonate.
참고문헌 (19)
- Black DM, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group", Lancet, 348, pp.1535~1541 (1996)
- Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group", JAMA, 282, pp.1344~1352 (1999)
- Chesnut CH 3rd, "Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis", J Bone Miner Res, 19, pp.1241~1249 (2004)
- Black DM, "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis", N Engl J Med, 356, pp.1809~1822 (2007)
- Brauer CA, "Using observational data for decision analysis and economic analysis", J Bone Joint Surg Am, 91(Suppl 3), pp.73~79 (2009)
- Bernstein J, "Decision analysis", J Bone Joint Surg Am, 79, pp.1404~1414 (1997)
- Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea", J Bone Miner Metab, 29, pp.744~751 (2011)
- Lee YK, "Persistence with intravenous zoledronate in elderly patients with osteoporosis", Osteoporos Int, 23, pp.2329~2333 (2012)
- Cramer JA, "Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis", Curr Med Res Opin, 21, pp.1453~1460 (2005)
- Cooper A, "Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study", Int J Clin Pract, 60, pp.896~905 (2006)
- Russell RG, "Mechanisms of action of bisphosphonates : similarities and differences and their potential influence on clinical efficacy", Osteoporos Int, 19, pp.733~759 (2008)
- Bilezikian JP, "Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis", Am J Med, 122, pp.S14~S21 (2009)
- Siris ES, "Impact of osteoporosis treatment adherence on fracture rates in North America and Europe", Am J Med, 122, pp.S3~S13 (2009)
- Hadji P, "GRAND : the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates", Osteoporos Int, 23, pp.223~231 (2012)
- Landfeldt E, "Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis(SARA)", Osteoporos Int, 23, pp.433~443 (2012)
- Kamatari M, "Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice : alendronate and risedronate", J Bone Miner Metab, 25, pp.302~309 (2007)
- Kertes J, "Factors contributing to compliance with osteoporosis medication", Isr Med Assoc J, 10, pp.207~213 (2008)
- Weycker D, "Compliance with osteoporosis drug therapy and risk of fracture", Osteoporos Int, 18, pp.271~277 (2007)
- Cramer JA, "A systematic review of persistence and compliance with bisphosphonates for osteoporosis", Osteoporos Int, 18, pp.1023~1031 (2007)